Drugs / GSI 136
Trials 2
| Phase | Registry id | Dates | Indication | Sponsor | Status | Outcome |
|---|---|---|---|---|---|---|
| Phase 1 | NCT00718731 | Mar → Aug 2008 | Alzheimer disease | Wyeth is now a wholly owned subsidiary of Pfizer | Completed | No outcome recorded |
| Phase 1 | NCT00719394 | Mar → Aug 2008 | Alzheimer disease | Wyeth is now a wholly owned subsidiary of Pfizer | Completed | No outcome recorded |
Evidence & citations 4 cited values
Every value below carries the sentence it was read from. 3 sources stand behind the page.
| Field | Value | Cited text |
|---|---|---|
| Known as | GSI 136 | ClinicalTrials.gov intervention name — accepted as the source's own label NCT00719394 ↗ |
| Action | Inhibit | “a gamma-secretase inhibitor” NCT00719394 ↗ |
| Modality | Small molecule | — CHEMBL480558 ↗ |
| Route | Oral | “GSI 136 Administered Orally” NCT00718731 ↗ |